Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae

Wei Zhang, Chunyu Yan, Shu-Rui Li, Tingting Fan, Shanshan Cao, Bin Cui, Mengying Li, Boyuan Fan, Bo Ji, Li Wang, Fei Cui, Jia Cui, Lei Wang, Yue Guan, Jingwen WangFrontiers in Cellular and Infection Microbiology 2023 · DOI

Abstract

In terms of adverse events, the safety of piperacillin–tazobactam (PTZ) was higher than that of meropenem in the treatment of complicated urinary tract infections (cUTIs).

Introduction

Complicated urinary tract infections (cUTIs) represent a significant clinical challenge, often involving structural abnormalities or catheter use. These infections are frequently driven by Gram-negative bacteria, such as E. coli and K. pneumoniae, that produce extended-spectrum $\beta$-lactamases (ESBLs). While carbapenems like meropenem have long been the gold standard for treating ESBL-producing infections, their extensive use has accelerated the emergence of carbapenem-resistant strains.

To preserve the utility of carbapenems, identifying effective "carbapenem-sparing" alternatives is critical. Piperacillin-tazobactam (PTZ) is a promising candidate, yet real-world comparative data against meropenem for cUTIs remains limited. This retrospective cohort study evaluates whether PTZ can serve as a safe and effective alternative to meropenem in clinical practice.

Methods

Researchers conducted a monocentric, retrospective cohort study at Xijing Hospital, China, analyzing data from January 2019 to November 2021. The study focused on adult patients with cUTIs caused by ESBL-producing Enterobacteriaceae susceptible to both PTZ and meropenem.

Patient selection procedures flowchart.

The final cohort consisted of 195 patients: 110 received PTZ and 85 received meropenem. Reflecting real-world clinical practice, dosages and durations were adjusted by practitioners based on individual patient needs, such as renal function. The primary endpoint was clinical success (resolution of symptoms without further antibiotics), while secondary endpoints included microbiological success, 90-day recurrence, rehospitalization, and safety metrics.

Results

The study found that PTZ performed comparably to meropenem across several key efficacy metrics:

  • Clinical Cure Rate: Success rates were statistically equivalent, with 80% in the PTZ group versus 78.8% in the meropenem group ($p = 0.84$).
  • Treatment and Hospitalization: Patients in the PTZ group experienced significantly shorter durations of antibiotic therapy (median 6 vs. 9 days, $p < 0.01$) and shorter hospital stays (median 16 vs. 22 days, $p = 0.010$).
  • Safety Profile: PTZ demonstrated a superior safety profile, with a significantly lower rate of adverse events (4.5%) compared to meropenem (15.3%, $p = 0.01$). Notably, liver function abnormalities were more frequent in the meropenem group (5.9%), while anaphylaxis was the primary concern for PTZ (2.7%).
  • Mortality: All-cause mortality was lower in the PTZ group (7.3% vs. 18.8%, $p = 0.015$), though this may be influenced by baseline differences in patient severity.

Discussion

These findings suggest that PTZ is a highly viable alternative to meropenem for treating ESBL-driven cUTIs. The equivalence in clinical and microbiological cure rates supports the implementation of carbapenem-sparing strategies, which are essential for mitigating the selection pressure that leads to carbapenem resistance.

Furthermore, the study demonstrates PTZ's effectiveness in a complex, real-world population characterized by significant comorbidities like diabetes and chronic kidney disease. By validating PTZ in these "messy" clinical settings, the research provides clinicians with the confidence to utilize PTZ as a first-line defense, reserving carbapenems for the most critical cases.

Limitations

The study's retrospective and monocentric nature introduces certain limitations, most notably selection bias. Patients in the meropenem group were generally older and sicker, which likely contributed to the observed differences in mortality and hospital stay. Additionally, the sample size of 195 patients limits the statistical power to fully control for all confounding variables. Future large-scale, multi-center randomized controlled trials are necessary to confirm these results and refine clinical guidelines for cost-effective, targeted antibiotic therapy.

Summary updated

Abstract

In terms of adverse events, the safety of PTZ was higher than that of meropenem in the treatment of cUTIs.
BibTeX
@inproceedings{zhang2023efficacy,
  author = {Wei Zhang and Chunyu Yan and Shu-Rui Li and Tingting Fan and Shanshan Cao and Bin Cui and Mengying Li and Boyuan Fan and Bo Ji and Li Wang and Fei Cui and Jia Cui and Lei Wang and Yue Guan and Jingwen Wang},
  title = {{Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1093842},
}
Figure